(NASDAQ: LNTH) Lantheus Holdings's forecast annual revenue growth rate of 7.86% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.61%.
Lantheus Holdings's revenue in 2026 is $1,541,609,000.On average, 15 Wall Street analysts forecast LNTH's revenue for 2026 to be $95,616,723,120, with the lowest LNTH revenue forecast at $90,254,433,918, and the highest LNTH revenue forecast at $105,695,242,584. On average, 15 Wall Street analysts forecast LNTH's revenue for 2027 to be $109,183,960,860, with the lowest LNTH revenue forecast at $99,105,441,396, and the highest LNTH revenue forecast at $126,175,310,982.
In 2028, LNTH is forecast to generate $125,529,252,042 in revenue, with the lowest revenue forecast at $108,085,660,662 and the highest revenue forecast at $149,433,432,822.